Jeongwu  Lee,  Ph.D.

Jeongwu Lee, Ph.D.

Associate Staff

Center for Cancer Stem Cell Research

Lerner Research Institute, 9500 Euclid Avenue, Cleveland, Ohio 44195
Location: NE6-209
Phone: (216) 444-9834


My laboratory studies the biology of glioblastoma multiforme (GBM), the most aggressive subtype of brain tumors. Cardinal features of GBM tumor cells include their stem cell-like behaviors and highly infiltrative/migratory nature, which are main reasons why GBM is such a fatal disease. Identification of unique signaling regulators operated in GBM stem cells (GSCs) might provide important clues for developing effective therapeutics against GBMs. We are focusing on a few key molecular pathways including; 1) Polycomb-mediated epigenetic gene silencing in the tumor initiation, maintenance, and invasion, 2) c-Met (receptor tyrosine kinase) signal transduction pathways in stemness and migration of these tumor cells, 3) Novel mitogenic signaling pathways that are specific to GSCs, and 4) Identification of radio- and chemo-sensitizing pathway to maximize therapeutic efficacy. By employing various aspects of stem cell biology and neuro oncology, we hope to better understand the underlying molecular mechanisms of GBM and provide potential therapeutic options.

Lee et al., Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastomas-initiating cells. (2008) Cancer Cell 13; 69-80.

Son et al., SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. (2009) Cell Stem Cell 4, 440-452.

Kim Y et al., Wnt activation is implicated in glioblastoma radioresistance. (2012) Lab Invest. 92:466-73.

Joo et al., MET signaling regulates glioblastoma stem cells. (2012) Cancer Research 72: 3828-38.

01/14/2019 |  

NCI-Funded Study Aims to Enhance Glioblastoma Treatment

Jeongwu Lee, PhD, Department of Cancer Biology, was awarded a five-year, $2.4 million grant from the National Cancer Institute, part of the National Institutes of Health, to study an FDA-approved drug to enhance treatment of glioblastoma (GBM), the most common and lethal form of brain cancer.